News | September 16, 2024
Laurus Labs inaugurates Rs. 250 crore R&D facility in Telangana
Total investment incurred for setting up the new R&D Rs 250 crore
Total investment incurred for setting up the new R&D Rs 250 crore
Target identification will commence on 17 September 2024, following the timeline provided in the campaign guidelines
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
The publication serves as a foundational tool for identifying gaps and addressing needs in various areas, including rural, urban, and tribal regions
MedTech Mitra initiative aims to empower MedTech innovators and advance healthcare solutions
TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
Agreement further expands Aptar Pharma’s leading respiratory portfolio
Subscribe To Our Newsletter & Stay Updated
